Biotech: Page 33
-
Permission granted by Sanjeev Luther.
Q&AClearing hurdles in rare cancer drug development
Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.
By Kim Ribbink • March 14, 2022 -
Getty Images
Q&A // Biotech SpotlightLiquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage
The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.
By Taren Grom • March 14, 2022 -
Explore the Trendline➔
Getty Images
TrendlineOncology R&D
Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.
By PharmaVoice staff -
Permission granted by Terry Weber
Q&ABiote CEO: Employers need to normalize women's health issues in the workforce
A survey by Biote reveals the impact of menopause on working women.
By Robin Robinson • March 14, 2022 -
Permission granted by Ultragenyx
Q&AUltragenyx's CEO on building a 'next-gen' rare disease company
How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.
By Kim Ribbink • March 9, 2022 -
Permission granted by Russell Potterfield.
ProfileFrom angel to operator: The unlikely journey of Endevica Bio's CEO
Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.
By Jared Whitlock • March 9, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Genentech's Quita Highsmith
Quita Highsmith is changing how Genentech approaches diversity and inclusion across the board — from drug development to career advancement.
By Taren Grom • March 9, 2022 -
Getty Images
ProfileHorizon’s VP of R&D on her ascent in biotech — and bringing other female scientists along for the ride
Elizabeth Thompson is guiding Horizon through new drug approvals while leading the way for young women in STEM.
By Alexandra Pecci • March 8, 2022 -
Getty Images
Two key factors behind NYC's record-setting rise in healthcare funding
According to a new report, women’s and digital health led to an explosion in funding last year in NYC.
By Robin Robinson • March 7, 2022 -
Getty Images
Are patients happy? This simple question could shake up clinical trials
The migration to DCTs is helping uncover critical gaps in patient experience.
By Kelly Bilodeau • March 4, 2022 -
Permission granted by Andrew Hopkins.
Q&AExscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
By Meagan Parrish • March 4, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter
With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.
By Taren Grom • March 2, 2022 -
Diego Camargo/PharmaVoice
The 2022 PharmaVoice 100 — new look, same drive for excellence
Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.
By Taren Grom • Feb. 28, 2022 -
Getty Images
Q&ACandel's CEO looks to help ignite a new era of cancer treatments
Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.
By Taren Grom • Feb. 28, 2022 -
Getty Images
Q&AWhy plasma derived therapies have a unique edge in rare diseases
Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.
By Kim Ribbink • Feb. 25, 2022 -
Permission granted by Guadalupe Hayes-Mota
ProfileGuadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues
A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company.
By Robin Robinson • Feb. 25, 2022 -
Diego Camargo/PharmaVoice
Podcast
Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo
Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.
By Taren Grom • Feb. 23, 2022 -
Getty Images
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Getty Images
ProfileHow Veru is developing blockbuster drugs while avoiding biotech's 'valley of death'
Why sexual health and telemedicine are key to the company's goals in oncology.
By Meagan Parrish • Feb. 16, 2022 -
Getty Images
Q&AWinning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
By Taren Grom • Feb. 11, 2022 -
Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Retrieved from Google image.
Q&AGaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
By Kelly Bilodeau • Feb. 8, 2022 -
Getty Images
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Retrieved from Google image.
OpinionIndustry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022
Previous
